| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 736.16 | 23.3% | 17.3% |
| Total Income | 735.59 | 22.1% | 16.6% |
| Expenditure | 625.07 | 14.1% | 25.0% |
| PBT | 110.52 | 102.4% | 15.7% |
| Net Profit | 80.95 | 107.0% | 6.8% |
| OPM | 22.90% | 5.69pp | 4.72pp |
| NPM | 11.00% | 4.51pp | 2.77pp |
| EPS | 18.76 | 106.8% | 6.8% |
Epigral Ltd Q4FY26: Revenue Up 17% to ₹736 Cr, Dividend ₹5
02 May 2026 · 2 May, 4:11 pm
Summary
Epigral Limited announced a strong performance for Q4FY26, achieving its highest-ever quarterly revenue of ₹736 crore, a 17% year-on-year and 22% sequential growth. Profit After Tax for the quarter rose sharply by 109% quarter-on-quarter to ₹82 crore, supported by improved EBITDA margins of 23%. While full-year FY26 revenue saw a marginal 1% decline to ₹2,542 crore, management highlighted strong demand recovery in Q4 and expects this momentum to continue into FY27. The company's ongoing capex projects for Epichlorohydrin and CPVC expansion are progressing as planned, poised to meet growing demand and enhance future financial performance.
Key Highlights
- 1
Epigral Ltd reported its highest-ever quarterly revenue of ₹736 crore in Q4FY26, registering a 17% year-on-year growth and a 22% sequential increase from Q3FY26.
- 2
Profit After Tax (PAT) for Q4FY26 significantly jumped by 109% quarter-on-quarter to ₹82 crore, though it was a slight decrease from ₹87 crore in Q4FY25.
- 3
The company's EBITDA margin improved to 23% in Q4FY26 from 17% in Q3FY26, reflecting enhanced operational efficiencies and normalized inventory costs.
- 4
For the full fiscal year 2026, revenue stood at ₹2,542 crore, experiencing a 1% drop due to a 4% decline in sales volume.
- 5
The Board proposed a final dividend of ₹5 per equity share, representing 50% of the face value, for FY2026.
- 6
Epigral spent ₹394 Crore on capex in FY2026, with ongoing projects set to expand CPVC Resin capacity to 1,50,000 TPA and Epichlorohydrin capacity to 1,00,000 TPA.
Management Comments
Maulik Patel
In Q4 FY26, we delivered record revenue of ₹736 crore, driven by a 15% sequential increase and 14% year-on-year growth in volumes. This performance reflects strong demand conditions and a full recovery post scheduled maintenance in Q3. Improved utilization levels and stabilization in raw material costs supported EBITDA margins of 23%. While FY26 saw some impact due to an extended monsoon and planned maintenance in the first half, demand recovery began in November and strengthened through Q4. We expect this momentum to continue into FY27, subject to global macro conditions.
Maulik Patel
Our diversified product portfolio continues to provide resilience amid geopolitical uncertainties, including developments in West Asia. At the same time, our ongoing capex projects for Epichlorohydrin and CPVC expansion are progressing as planned and within budget. Once commissioned, these plants will address India’s growing demand and enhance our financial performance. With these projects nearing completion and a pipeline of new initiatives focused on further integration, we are well- positioned to deliver consistent growth and long-term value for our stakeholders.
Informational and educational content only. Not investment advice.